Entrada Therapeutics, Inc

TRDANASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

38.9M

on 2026-06-30, from 33.6M on 2024-03-31 10-Q ↗

Newest

$400.0M

S-3 of 2025-11-06. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗

$150.0M

TD Securities (USA), agreement of 2025-11-06. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

The 10-Q filed 2026-08-05 is not read yet.

Cash

2.9 quarters

$99.3M on 2026-06-30 ÷ $33.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 5 of its filings are not read yet.